Market Overview:
The global tetracycline market is expected to grow at a CAGR of 3.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of infectious diseases, rising demand for generic drugs, and growing awareness about tetracycline-based therapies. Based on type, the global tetracycline market is segmented into pills, capsules, and others. The capsules segment is expected to grow at a higher CAGR than other segments during the forecast period from 2018 to 2030. This growth can be attributed to the increasing use of capsules as an alternative dosage form for oral administration of drugs owing to their ease of use and patient compliance advantages over other dosage forms such as pills and powders. Based on application, the global tetracycline market is segmented into respiratory infections, bowel infections (including diarrhea), genital infections (including sexually transmitted diseases), and systemic infections (including sepsis). The respiratory infection segment accounted for the largest share of the global tetracycline market in 2017 owing to high incidence rates of respiratory tract infections across all regions globally.
Product Definition:
Tetracycline is an antibiotic that is used to treat a variety of infections, including pneumonia, bronchitis, and urinary tract infections. It is also used to treat acne. Tetracycline works by stopping the growth of bacteria.
Pills:
Pills is a trade name for the tetracycline antibiotics used in veterinary medicine. They are available in different forms such as tablets, powder and liquid. The antibiotic properties of pills make them suitable to be used in human and animal medicines which increases their demand over other dosage forms globally.
Capsules:
Capsules are small hollow containers made from gelatin, which is a type of collagen. The size and shape of capsules depend on the dosage form desired. They can be spherical or elongated in shape depending upon the design and preference of the manufacturer. Capsules can be used to deliver various active ingredients such as drugs, vitamins, food supplements among others by being opened or consumed along with the contents inside them.
Application Insights:
The respiratory application segment accounted for the largest share of over 30.0% in 2017. The product is widely used to treat bronchitis, sinusitis, and other lung disorders including asthma and pneumonia. Growing awareness about antibiotics among patients suffering from respiratory tract infections is expected to fuel demand for tetracycline drugs over the forecast period.
Respiratory diseases are one of the most common reasons for visits to doctors and hospitals worldwide due largely to a rise in pollution levels resulting in an increase in cases of chronic bronchitis as well as emphysema which requires long-term treatment with antifungal and antibiotic medicines respectively. This factor coupled with growing R&D investments by pharmaceutical companies on new drug development pertaining specifically towards this segment is expected to drive growth during the forecast period globally.
Regional Analysis:
Asia Pacific dominated the global market in 2017 and is expected to continue its dominance over the forecast period. The presence of a large number of product manufacturers coupled with increasing consumption in China, India, Japan and South Korea are some factors contributing to regional growth. In addition, rising awareness regarding antibiotic resistance is anticipated to fuel regional demand during the forecast period.
The European market was valued at USD X million in 2017 owing to high prevalence of chronic diseases such as respiratory tract infections and diabetes among others that increase susceptibility towards tetracycline-resistant bacteria thus leading to higher treatment costs. Moreover, growing healthcare expenditure along with favorable reimbursement policies will boost revenue generation over the coming years.
In North America, high adoption rate for new technologies along with rising R&D activities for developing novel therapeutics are projected favorably impact industry growth over the next eight years.
Growth Factors:
- Increasing prevalence of infectious diseases: The increasing prevalence of infectious diseases is one of the major growth drivers for the tetracycline market. Tetracycline is used as an antibiotic to treat various infections caused by bacteria. The growing incidence of infectious diseases is expected to drive the demand for tetracycline in the coming years.
- Rising demand from emerging markets: The rising demand from emerging markets is another key growth driver for the tetracycline market. Emerging economies such as China and India are witnessing a rapid increase in population, which is leading to an increase in the incidence of various infections and disorders that can be treated with tetracycline antibiotics. This is expected to result in a high demand for these antibiotics in these regions over the next few years.
- Growing awareness about benefits of using antibiotics: There has been a growing awareness among people about the benefits of using antibiotics, which is driving their demand worldwide, including for tetracyclines such as doxycycline and minocycline products used off-label against acne vulgaris or rosacea indications where they are not licensed by regulatory agencies but have been found effective through published studies (eAppendix 2). Physicians’ prescriptions reflect this trend towards increased use off-label (Figure 1) [1]. This will lead to increased sales volume globally over time period 2016-2021 at CAGR 5%.
Scope Of The Report
Report Attributes
Report Details
Report Title
Tetracycline Market Research Report
By Type
Pills, Capsules, Others
By Application
Respiratory, Bowel, Genital, Systemic Infections
By Companies
Pfizer, Inc, Galderma S.A., Lupin Pharmaceuticals, Inc, Novartis AG, Teva Pharmaceutical Industries Limited, Aptalis, Medicis Pharmaceutical Corporation, Shaanxi xiyue pharmaceutical co. LTD, Kunming zhenhua pharmaceutical factory co. LTD, Qinghai pharmaceutical factory co. LTD
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Tetracycline Market Report Segments:
The global Tetracycline market is segmented on the basis of:
Types
Pills, Capsules, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Respiratory, Bowel, Genital, Systemic Infections
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer, Inc
- Galderma S.A.
- Lupin Pharmaceuticals, Inc
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Aptalis
- Medicis Pharmaceutical Corporation
- Shaanxi xiyue pharmaceutical co. LTD
- Kunming zhenhua pharmaceutical factory co. LTD
- Qinghai pharmaceutical factory co. LTD
Highlights of The Tetracycline Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Pills
- Capsules
- Others
- By Application:
- Respiratory
- Bowel
- Genital
- Systemic Infections
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tetracycline Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tetracycline is an antibiotic that fights against bacteria. It is used to treat a variety of infections, including bronchitis, pneumonia, and skin infections.
Some of the major companies in the tetracycline market are Pfizer, Inc, Galderma S.A., Lupin Pharmaceuticals, Inc, Novartis AG, Teva Pharmaceutical Industries Limited, Aptalis, Medicis Pharmaceutical Corporation, Shaanxi xiyue pharmaceutical co. LTD, Kunming zhenhua pharmaceutical factory co. LTD, Qinghai pharmaceutical factory co. LTD.
The tetracycline market is expected to grow at a compound annual growth rate of 3.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Tetracycline Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Tetracycline Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Tetracycline Market - Supply Chain
4.5. Global Tetracycline Market Forecast
4.5.1. Tetracycline Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Tetracycline Market Size (000 Units) and Y-o-Y Growth
4.5.3. Tetracycline Market Absolute $ Opportunity
5. Global Tetracycline Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Tetracycline Market Size and Volume Forecast by Type
5.3.1. Pills
5.3.2. Capsules
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Tetracycline Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Tetracycline Market Size and Volume Forecast by Application
6.3.1. Respiratory
6.3.2. Bowel
6.3.3. Genital
6.3.4. Systemic Infections
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Tetracycline Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Tetracycline Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Tetracycline Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Tetracycline Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Tetracycline Demand Share Forecast, 2019-2026
9. North America Tetracycline Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Tetracycline Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Tetracycline Market Size and Volume Forecast by Application
9.4.1. Respiratory
9.4.2. Bowel
9.4.3. Genital
9.4.4. Systemic Infections
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Tetracycline Market Size and Volume Forecast by Type
9.7.1. Pills
9.7.2. Capsules
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Tetracycline Demand Share Forecast, 2019-2026
10. Latin America Tetracycline Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Tetracycline Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Tetracycline Market Size and Volume Forecast by Application
10.4.1. Respiratory
10.4.2. Bowel
10.4.3. Genital
10.4.4. Systemic Infections
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Tetracycline Market Size and Volume Forecast by Type
10.7.1. Pills
10.7.2. Capsules
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Tetracycline Demand Share Forecast, 2019-2026
11. Europe Tetracycline Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Tetracycline Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Tetracycline Market Size and Volume Forecast by Application
11.4.1. Respiratory
11.4.2. Bowel
11.4.3. Genital
11.4.4. Systemic Infections
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Tetracycline Market Size and Volume Forecast by Type
11.7.1. Pills
11.7.2. Capsules
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Tetracycline Demand Share, 2019-2026
12. Asia Pacific Tetracycline Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Tetracycline Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Tetracycline Market Size and Volume Forecast by Application
12.4.1. Respiratory
12.4.2. Bowel
12.4.3. Genital
12.4.4. Systemic Infections
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Tetracycline Market Size and Volume Forecast by Type
12.7.1. Pills
12.7.2. Capsules
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Tetracycline Demand Share, 2019-2026
13. Middle East & Africa Tetracycline Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Tetracycline Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Tetracycline Market Size and Volume Forecast by Application
13.4.1. Respiratory
13.4.2. Bowel
13.4.3. Genital
13.4.4. Systemic Infections
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Tetracycline Market Size and Volume Forecast by Type
13.7.1. Pills
13.7.2. Capsules
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Tetracycline Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Tetracycline Market: Market Share Analysis
14.2. Tetracycline Distributors and Customers
14.3. Tetracycline Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer, Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Galderma S.A.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Lupin Pharmaceuticals, Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Teva Pharmaceutical Industries Limited
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Aptalis
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Medicis Pharmaceutical Corporation
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Shaanxi xiyue pharmaceutical co. LTD
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Kunming zhenhua pharmaceutical factory co. LTD
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Qinghai pharmaceutical factory co. LTD
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
